MyPrurigoTeam

What has your experience been with JAK inhibitors like ruxolitinib (Opzelura) for prurigo nodularis?

Ruxolitinib cream is currently being studied for prurigo nodularis in clinical trials, though it's not yet FDA-approved for this condition. It's already approved for treating mild to moderate atopic dermatitis and vitiligo.

What has your experience been with JAK inhibitors like ruxolitinib (Opzelura) for prurigo nodularis?

Ruxolitinib cream is currently being studied for prurigo nodularis in clinical trials, though it's not yet FDA-approved for this condition. It's already approved for treating mild to moderate atopic dermatitis and vitiligo.

Recent clinical trial results showed promising outcomes:

- Nearly 45% of people using 1.5% ruxolitinib cream experienced significant itch relief after 12 weeks
- Some participants saw results as early as one week, with over 22% meeting the itch-reduction threshold
- About 12% achieved both reduced itch and visible skin improvement by week 12

Common side effects were generally mild and included:
- Cold symptoms
- Headache
- Diarrhea
- High blood pressure
- Viral stomach flu

If approved, ruxolitinib cream could become the first topical treatment for prurigo nodularis, offering a needle-free alternative to the currently approved injectable medications.

Since this is still in clinical trials, talk with your dermatologist about whether it might be an option for you or if other approved treatments would be better suited for your situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

45% Find Itch Relief From Ruxolitinib Cream in Clinical Trials